STAT6 and allergic asthma: The development of siRNA-based methods for targeting disease-associated gene expression holds great promise as the basis for new therapeutics [29], [30] and in applying this concept to allergic asthma we have demonstrated that STAT6, a key regulatory molecule within the IL-13 pathway, is amenable to targeted suppression with siRNA [12].